Skip to main content
. 2020 Mar 17;11(11):956–968. doi: 10.18632/oncotarget.27493

Figure 3. Number of antibody-secreting cells is reduced in sensitive cell lines.

Figure 3

(A) Light chain secretion quantified by ELISA in supernatants from 6 sensitive (MM-1-S, OPM-2, KMS-21BM, RPMI8826, NCI-H929 and KMS-20) and 6 insensitive cell lines (AMO-1, KMM-1, KMS-11, U266B1, KMS-27 and L-363) without DOT1L inhibitor treatment (DMSO only). OD 405: optical density at 405 nm. Bar graphs show the mean ± s. d. (B) Enumeration of antibody-secreting cells (ASCs) by ELISPOT in 6 sensitive and 6 insensitive cell lines treated with either 1 μM SGC0946 or DMSO for the indicated durations. The y-axis represents the log2 ratio of ASCs in the SGC0946-treated compared to the DMSO group. L: lambda chain, K: kappa chain.